Literature DB >> 12702913

Diagnosis of fatty liver disease: is biopsy necessary?

Diamond Joy1, Vallipuram R Thava, Brian B Scott.   

Abstract

Non-alcoholic fatty liver disease is increasingly being recognized as an important and common condition, affecting approximately 20% of the general population. Although liver biopsy is currently the gold standard for diagnosis, there is a need for less invasive methods. Imaging by ultrasound, computerized tomography and magnetic resonance are all able to demonstrate fat. In this paper, these three imaging techniques are critically assessed. Ultrasound, although probably not the most reliable imaging method, has many advantages and, when positive, gives a high degree of certainty of the diagnosis depending on the prevalence of fatty liver in the population being studied. Unlike liver biopsy, none of these techniques is able to differentiate simple steatosis from non-alcoholic steatohepatitis.

Entities:  

Mesh:

Year:  2003        PMID: 12702913     DOI: 10.1097/01.meg.0000059112.41030.2e

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  84 in total

1.  Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women.

Authors:  Seong-Su Moon; Young-Sil Lee; Sung Woo Kim
Journal:  Endocrine       Date:  2012-03-11       Impact factor: 3.633

2.  Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Mitsuhito Koizumi; Shinya Furukawa; Teruhisa Ueda; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Yoichi Hiasa; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

3.  Simultaneous assessment of liver volume and whole liver fat content: a step towards one-stop shop preoperative MRI protocol.

Authors:  Gaspard d'Assignies; Claude Kauffmann; Yvan Boulanger; Marc Bilodeau; Valérie Vilgrain; Gilles Soulez; An Tang
Journal:  Eur Radiol       Date:  2010-09-03       Impact factor: 5.315

4.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

5.  Biermer's anemia: a new cause of cholestasis and hepatic steatosis?

Authors:  Xavier Roblin; Maud Genevois; V Ducros; Jean-Pierre Zarski; Vincent Leroy
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

Review 6.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

7.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

8.  Probable NAFLD, by ALT levels, and diabetes among Filipino-American women.

Authors:  Charlene A Wong; Maria Rosario G Araneta; Elizabeth Barrett-Connor; John Alcaraz; Donna Castañeda; Carol Macera
Journal:  Diabetes Res Clin Pract       Date:  2007-08-30       Impact factor: 5.602

9.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

10.  Non-invasive means of measuring hepatic fat content.

Authors:  Sanjeev-R Mehta; E-Louise Thomas; Jimmy-D Bell; Desmond-G Johnston; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.